The Food and Drug Administration granted full approval to remdesivir for Covid-19 treatment. It’s the first drug to receive this designation. | Fadel Dawood/Picture Alliance via Getty Images

Researchers are concerned the FDA’s first full approval of a Covid-19 drug doesn’t have enough research behind it.

The Food and Drug Administration on Thursday gave its first full approval for a drug to treat Covid-19 to the antiviral remdesivir. But some researchers say the FDA is once again promoting a Covid-19 therapy based on shaky evidence.

Developed by Gilead Sciences and marketed under the brand name Veklury, remdesivir previously received emergency use authorization from the FDA in May, which allowed it to be used to treat patients with severe Covid-19. In August, the FDA relaxed its guidelines to allow the drug to be used in less serious cases. President Donald Trump also took the drug